A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis
A Moore, KB Gordon, S Kang, A Gottlieb… - Journal of the American …, 2007 - Elsevier
… OBJECTIVE: In this randomized, open-label study, we evaluated the effectiveness and
safety of continuous versus interrupted etanercept therapy. METHODS: All patients received …
safety of continuous versus interrupted etanercept therapy. METHODS: All patients received …
A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19
Y Doi, M Hibino, R Hase, M Yamamoto… - Antimicrobial agents …, 2020 - Am Soc Microbiol
Favipiravir is an oral broad-spectrum inhibitor of viral RNA-dependent RNA polymerase that
is approved for treatment of influenza in Japan. We conducted a prospective, randomized, …
is approved for treatment of influenza in Japan. We conducted a prospective, randomized, …
GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial
B Cryer, C Li, LS Simon, G Singh… - Official journal of the …, 2013 - journals.lww.com
OBJECTIVES: Because of the limitations of randomized controlled trials (RCTs) and observational
studies, a prospective, randomized, open-label, blinded endpoint (PROBE) study may …
studies, a prospective, randomized, open-label, blinded endpoint (PROBE) study may …
[HTML][HTML] Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled …
I Chytra, M Stepan, J Benes, P Pelnar, A Zidkova… - Critical care, 2012 - Springer
Introduction Meropenem bactericidal activity depends on the time when the free drug
concentrations remain above the minimum inhibitory concentration of pathogens. The goal of this …
concentrations remain above the minimum inhibitory concentration of pathogens. The goal of this …
Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136
C Katlama, MA Valantin, M Algarte-Genin, C Duvivier… - Aids, 2010 - journals.lww.com
… MONOtherapy Inhibitor protease is a prospective, open-label, noninferiority, 96-week safety
and efficacy trial in virologically suppressed patients on triple therapy who were randomized …
and efficacy trial in virologically suppressed patients on triple therapy who were randomized …
Treatment of Churg‐Strauss syndrome without poor‐prognosis factors: a multicenter, prospective, randomized, open‐label study of seventy‐two patients
… We conducted a multicenter, prospective, randomized, open-label trial in France and Belgium
under the auspices of the FVSG and the European Vasculitis Study Group (EUVAS). The …
under the auspices of the FVSG and the European Vasculitis Study Group (EUVAS). The …
[HTML][HTML] Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial
S JamaliMoghadamSiahkali, B Zarezade… - European journal of …, 2021 - Springer
Background Vitamin C is an essential water-soluble nutrient that functions as a key antioxidant
and has been proven to be effective for boosting immunity. In this study, we aimed to …
and has been proven to be effective for boosting immunity. In this study, we aimed to …
The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer
OBJECTIVE To evaluate the efficacy and safety of degarelix, a new gonadotrophin‐releasing
hormone (GnRH) antagonist (blocker), vs leuprolide for achieving and maintaining …
hormone (GnRH) antagonist (blocker), vs leuprolide for achieving and maintaining …
[HTML][HTML] A randomized, open‐label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients
Chronic hepatitis C is the most common indication for liver transplantation, but viral recurrence
is universal and progressive graft injury occurs in most recipients. Our aim was to assess …
is universal and progressive graft injury occurs in most recipients. Our aim was to assess …
… once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal …
J Rosenstock, D Raccah, L KORanyi, L Maffei… - Diabetes …, 2013 - Am Diabetes Assoc
… 1c 7–10%) with metformin were randomized to lixisenatide 20 μg once daily (n = 318) or
exenatide 10 μg twice daily (n = 316) in a 24-week (main period), open-label, parallel-group, …
exenatide 10 μg twice daily (n = 316) in a 24-week (main period), open-label, parallel-group, …